Showing results (571-580 of 2,640) with videos related to

Sort By:
Pageof 264
Hematology (Amsterdam, Netherlands)|May 18, 2023
Pediatric immune thrombocytopenia: a focus on eltrombopag as second-line therapyGiuseppe Palumbo, Piero Farruggia, Ugo Ramenghi, et al.
Hematology (Amsterdam, Netherlands)|May 11, 2023
The prognostic role of lymphocyte to monocyte ratio (LMR) in patients with Myelodysplastic NeoplasmsChuanyang Lu, Qiuni Chen, Jiaxin Li, et al.
Hematology (Amsterdam, Netherlands)|May 12, 2023
Identification of FCER1G as a key gene in multiple myeloma based on weighted gene co-expression network analysisXiao Qiu, Jia-He Zhang, Ying Xu, et al.
Hematology (Amsterdam, Netherlands)|May 3, 2023
Abatacept as salvage therapy for life-threatening refractory autoimmune hemolytic anemia: a case reportJoerg Hoffmann, Georg Schliesser, Andreas Neubauer
Hematology (Amsterdam, Netherlands)|April 4, 2023
miR-100-5p is upregulated in multiple myeloma and involves in the pathogenesis of multiple myeloma through targeting MTMR3Xiaofang Wei, Youfan Feng, Yuan Fu, et al.
Hematology (Amsterdam, Netherlands)|August 14, 2025
Identification of prospective novel drug targets for immune thrombocytopenia by integrating plasma proteomeWei He, Jingcheng Zhang, Mingzhe Zhao, et al.
Hematology (Amsterdam, Netherlands)|August 5, 2025
Retrospective analysis of ruxolitinib as induction treatment in pediatric hemophagocytic lymphohistiocytosisShu-Yi Guo, Jun-Yan Han, Kun-Yin Qiu, et al.
Hematology (Amsterdam, Netherlands)|August 4, 2025
Research progress on Anoikis in hematological diseases: a literature reviewWencong Luo, Yundong Chen, Xiaoyu Yao, et al.
Hematology (Amsterdam, Netherlands)|July 22, 2025
Pharmacovigilance and signal detection of adverse drug events associated with proteasome inhibitors in multiple myeloma: a real-world analysis using the FAERS databaseJunYun Luo, Shupeng Chen, Meiling Zhang, et al.
Hematology (Amsterdam, Netherlands)|July 24, 2025
Meta-analysis of the prognostic efficacy of daratumumab combined with standard therapy in high-risk multiple myelomaHongmei Zhou, Min Zhang, Yi Jin, et al.
Pageof 264